{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-302045","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2026-07-13T20:19:36+00:00","discovered_at":"2026-07-13T20:20:01.513740+00:00","generated_at":"2026-07-13T20:20:09.099574+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Erasca reports 57% uORR at 8 weeks for ERAS-0015 in KRAS G12X PDAC; plans pivotal trials in 2027","bullets":["57% uORR at 8 weeks in 2L+ KRAS G12X PDAC at 32 mg QD RDE (N=7).","Safety: mostly low-grade TRAEs, no DLTs, no discontinuations due to TRAEs; median relative dose intensity 100%.","Combination with panitumumab in mCRC: no DLTs in 16 mg cohort; dose escalation ongoing.","Plans: registration-enabling trial in NSCLC 2L+ in H1 2027; Phase 3 pivotal in PDAC 1L in 2027; Phase 3 pivotal in RAS-mutant NSCLC in H2 2027/H1 2028.","One Grade 3 pneumonitis event progressed to Grade 5 after withdrawal of supportive care."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-302045","json":"https://secwatch.observer/filing/0001193125-26-302045.json","markdown":"https://secwatch.observer/filing/0001193125-26-302045.md","text":"https://secwatch.observer/filing/0001193125-26-302045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000119312526302045/0001193125-26-302045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000119312526302045/d54726d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-13T20:20:09.099574+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}